Claim: Indivior, a specialty pharmaceuticals business, is a spinoff of Reckitt Benckiser and was capitalized at £2.3 billion (US$3.1 billion) on the London Stock Exchange in 2015.
Evidence: Indivior is a specialty pharmaceuticals business. In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior. By February 2015, the company was capitalised at £2.3 billion (US$3.1 billion) on the London Stock Exchange.